drugset / Trial / NCT03059498
PECS Block: Plasma Bupivacaine Level
Non-randomizedParallel-groupOpen-labelOther
Summary
The purpose of this study is to determine peak plasma bupivacaine concentrations in a similar fashion for PECS I/II blocks. The investigators hypothesis is that the mean peak plasma levels for patients undergoing PECS I/II blocks will be less than the levels reported to cause early neurotoxicity of \[2.2 (0.9) micrograms/ml\]6 in patients receiving intravenous bupivacaine infusions.
Timeline
- Start
- 2017-06-06
- Primary completion
- 2017-11-15
- Completion
- 2017-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bupivacaine | Other / unclassified | 0.25 % | Other |
| Comparator | Bupivacaine | Other / unclassified | 30 ml | Other |
Indications
No indication recorded.